These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 4734403)

  • 41. Evidence for the presence of components of the alternative (properdin) pathway of complement activation in respiratory secretions.
    Robertson J; Caldwell JR; Castle JR; Waldman RH
    J Immunol; 1976 Sep; 117(3):900-3. PubMed ID: 956659
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Proceedings: Metabolism of C3 and glycine-rich beta glycoprotein (GBG) in hypocomplementaemia.
    Peters DK; Charlesworth JA; Williams DG; Sissons JG; Lachmann PJ
    Clin Sci Mol Med; 1974 Feb; 46(2):17P. PubMed ID: 4817262
    [No Abstract]   [Full Text] [Related]  

  • 43. Isolation of the anticomplementary protein from cobra venom and its mode of action on C3.
    Müller-Eberhard HJ; Fjellström KE
    J Immunol; 1971 Dec; 107(6):1666-72. PubMed ID: 5120401
    [No Abstract]   [Full Text] [Related]  

  • 44. Primary structure of cobra complement component C3.
    Fritzinger DC; Petrella EC; Connelly MB; Bredehorst R; Vogel CW
    J Immunol; 1992 Dec; 149(11):3554-62. PubMed ID: 1431125
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Studies in vivo and in vitro on an abnormality in the metabolism of C3 in a patient with increased susceptibility to infection.
    Alper CA; Abramson N; Johnston RB; Jandl JH; Rosen FS
    J Clin Invest; 1970 Nov; 49(11):1975-85. PubMed ID: 4097977
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assembly of the membrane attack complex promotes decay of the alternative pathway C3 convertase on Neisseria gonorrhoeae.
    Densen P; McRill CM; Ross SC
    J Immunol; 1988 Dec; 141(11):3902-9. PubMed ID: 3141507
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The properdin system and immunity. V. The bactericidal activity of the properdin system.
    WARDLAW AC; PILLEMER L
    J Exp Med; 1956 May; 103(5):553-75. PubMed ID: 13319578
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A serum factor in chronic hypocomplementemic hephritis distinct from immunoglobulins and activating the alternate pathway of complement.
    Vallota EH; Götze O; Spiegelberg HL; Forristal J; West CD; Müller-Eberhard HJ
    J Exp Med; 1974 May; 139(5):1249-61. PubMed ID: 4207623
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.
    Pangburn MK; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1978 May; 75(5):2416-20. PubMed ID: 276881
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum proteins involved in decay and regeneration of cobra venom factor-dependent complement activation.
    Fearon DT; Austen KF; Ruddy S
    J Immunol; 1973 Dec; 111(6):1730-6. PubMed ID: 4796101
    [No Abstract]   [Full Text] [Related]  

  • 51. Complement activation in semisolid media: insolubilization of alternative pathway convertases in agar gels with C3 nephritic factor-containing sera.
    Arnaout MA; Davis AE; Rosen RS; Alper CA
    J Immunol; 1977 Oct; 119(4):1316-20. PubMed ID: 894039
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Escherichia coli bacteremia in the squirrel monkey. I. Effect of cobra venom factor treatment.
    Gilbert DN; Barnett JA; Sanford JP
    J Clin Invest; 1973 Feb; 52(2):406-13. PubMed ID: 4630602
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Heat labile opsonins to pneumococcus. II. Involvement of C3 and C5.
    Shin HS; Smith MR; Wood WB
    J Exp Med; 1969 Dec; 130(6):1229-41. PubMed ID: 4390900
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relative importance of C3b inactivator and beta 1H globulin in the modulation of the properdin amplification loop in systemic lupus erythematosus.
    Whaley K; Schur PH; Ruddy S
    Clin Exp Immunol; 1979 Jun; 36(3):408-14. PubMed ID: 114347
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Activation of the alternative pathway of complement by Entamoeba histolytica.
    Ortiz-Ortiz L; Capin R; Capin NR; Sepúlveda B; Zamacona G
    Clin Exp Immunol; 1978 Oct; 34(1):10-8. PubMed ID: 219975
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Properdin binding to complement activating surfaces depends on initial C3b deposition.
    Harboe M; Johnson C; Nymo S; Ekholt K; Schjalm C; Lindstad JK; Pharo A; Hellerud BC; Nilsson Ekdahl K; Mollnes TE; Nilsson PH
    Proc Natl Acad Sci U S A; 2017 Jan; 114(4):E534-E539. PubMed ID: 28069958
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera.
    Baatrup G; Jonsson H; Sjöholm A; Sturfelt G; Svehag SE
    J Clin Lab Immunol; 1988 Jun; 26(2):73-9. PubMed ID: 3264027
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Passive hemolysis by serum and cobra venom factor: a new mechanism inducing membrane damage by complement.
    Pickering RJ; Wolfson MR; Good RA; Gewurz H
    Proc Natl Acad Sci U S A; 1969 Feb; 62(2):521-7. PubMed ID: 4978744
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Modulation of the properdin amplification loop in membranoproliferative and other forms of glomerulonephritis.
    Whaley K; Ward D; Ruddy S
    Clin Exp Immunol; 1979 Jan; 35(1):101-6. PubMed ID: 85507
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro synthesis of factor B of the alternative pathway of complement activation by mouse peritoneal macrophages.
    Bentley C; Bitter-Suermann D; Hadding U; Brade V
    Eur J Immunol; 1976 Jun; 6(6):393-8. PubMed ID: 1033069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.